Literature DB >> 33999110

Market Exclusivity and Changes in Competition and Prices Associated With the US Food and Drug Administration Unapproved Drug Initiative.

Simon J Gunter1,2, Aaron S Kesselheim1,2, Benjamin N Rome1,2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33999110      PMCID: PMC8129902          DOI: 10.1001/jamainternmed.2021.1989

Source DB:  PubMed          Journal:  JAMA Intern Med        ISSN: 2168-6106            Impact factor:   21.873


× No keyword cloud information.
  1 in total

1.  The Vexing Voyage of Vasopressin: The Consequences of Granting Market Exclusivity to Unapproved Drugs.

Authors:  Liam Bendicksen; Aaron S Kesselheim; Benjamin N Rome
Journal:  Chest       Date:  2022-08       Impact factor: 10.262

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.